ReviewFrontiers in immunology2021
Immunomodulatory Effects of Mesenchymal Stem Cells on Drug-Induced Acute Kidney Injury.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Therapeutic Potential of Mesenchymal Stem Cells in Pediatric Kidney Disorders: A Comprehensive Review.Health science reports · 2026Article
- Advancing mesenchymal stem cell therapy for kidney diseases in companion animals: from mechanisms to clinical application.Frontiers in veterinary science · 2026Review
- Total Glucosides of Paeony Alleviates Acute Kidney Injury by Inhibiting Dendritic Cells and T-Cell Communication.Advances in pharmacological and pharmaceutical sciences · 2026Article
- Innovative strategies to enhance MSCs efficacy in acute kidney injury (Review).International journal of molecular medicine · 2025Review
- Emerging role of mesenchymal stem cell-derived exosomes in the repair of acute kidney injury.World journal of stem cells · 2025Review
- Ultrasound-guided renal subcapsular transplantation of mesenchymal stem cells for treatment of acute kidney injury in a minipig model: safety and efficacy evaluation.Stem cell research & therapy · 2025Article
- Traditional Chinese Medicine and renal regeneration: experimental evidence and future perspectives.Chinese medicine · 2024Review
- Immunomodulatory performance of GMP-compliant, clinical-grade mesenchymal stromal cells from four different sources.Heliyon · 2024Article
- Advances in the Treatment of Kidney Disorders using Mesenchymal Stem Cells.Current pharmaceutical design · 2024Review
- Asian Pigeonwing Plants (Pharmaceuticals (Basel, Switzerland) · 2022Article
- Recent research on the mechanism of mesenchymal stem cells in the treatment of bronchopulmonary dysplasia.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced nephrotoxicity is an important and increasing cause of acute kidney injury (AKI), which accounts for approximately 20% of hospitalized patients. Previous reviews studies on immunity and AKI focused mainly on ischemia-reperfusion (IR), whereas no systematic review addressing drug-induced AKI and its related immune mechanisms is available. Recent studies have provided a deeper understanding on the mechanisms of drug-induced AKI, among which acute tubular interstitial injury induced by the breakdown of innate immunity was reported to play an important role. Emerging research on mesenchymal stem cell (MSC) therapy has revealed its potential as treatment for drug-induced AKI. MSCs can inhibit kidney damage by regulating the innate immune balance, promoting kidney repair, and preventing kidney fibrosis. However, it is important to note that there are various sources of MSCs, which impacts on the immunomodulatory ability of the cells. This review aims to address the immune pathogenesis of drug-induced AKI versus that of IR-induced AKI, and to explore the immunomodulatory effects and therapeutic potential of MSCs for drug-induced AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.